Every registered 503B outsourcing facility must renew its FDA registration and pay its annual establishment fee between October 1 and December 31, or the facility is removed from the list of registered outsourcing facilities on January 1. FDA resets the establishment and reinspection fee rates every fiscal year, runs the small business fee reduction on a separate deadline of its own, and expects a semiannual product report on a schedule that does not move with the renewal window. Missing one of these dates does not pause the others, and each carries its own consequence for a facility's registered status.
The Annual Registration Renewal Window
FDA requires every outsourcing facility to re-register between October 1 and December 31 of each calendar year, the same window every year regardless of when the facility first registered. A facility that does not complete the renewal, including payment of the annual establishment fee, during that window is removed from the list of registered outsourcing facilities on January 1. That list is what separates an outsourcing facility from a 503A/503B compounder; falling off it costs outsourcing-facility status, not just a late invoice. Registering for the first time is covered separately in Registering as a 503B Outsourcing Facility, and what has to stay current after that is covered in 503B Reporting Obligations After Registration. This guide covers what changes every fiscal year: the fee amount and the renewal clock itself.
FY2027 Establishment and Reinspection Fees
For fiscal year 2027, which runs from October 1, 2026 through September 30, 2027, FDA set the non-small business annual establishment fee at $22,074 and the reduced small business establishment fee at $7,142, a fraction set by statute at roughly one-third of the standard rate. The reinspection fee for FY2027 is $21,427, and FDA applies no small business reduction to that fee; a facility FDA reinspects pays the full reinspection amount regardless of size. FDA emails the reinspection invoice to the address in the facility's registration file, and payment is due within 30 days of the invoice date. The establishment fee invoice runs on a shorter clock: FDA treats the registration as withdrawn if the facility does not pay the full amount within 15 calendar days after FDA issues the invoice. The establishment fee funds FDA's ongoing cGMP oversight of outsourcing facilities, a layer of federal compliance separate from whatever the facility already pays its state board of pharmacy.
Qualifying for the Small Business Fee Reduction
The reduced rate is not automatic. FDA limits it to a facility with gross annual sales of $1,000,000 or less in the 12 months ending April 1 of the preceding fiscal year, and runs the request on its own deadline, separate from the registration renewal window. A facility seeking the small business exception for a given fiscal year submits FDA Form 3908 to FDA's user fee office by April 30, before that fiscal year begins on October 1. The window to request the FY2027 reduction ran from April 1 through April 30, 2026, and has already closed; a facility that missed it pays the full non-small business establishment fee for FY2027 regardless of its actual size, and has to plan ahead for the FY2028 window instead.
A facility can pay its fee on time and still lose its outsourcing-facility exemptions if the product report lapses.
Semiannual Product Reporting Runs on Its Own Schedule
Separate from the annual registration cycle, every outsourcing facility submits a drug product report twice each year, in June and December, each covering the preceding six-month production period. A report submitted in June covers products compounded from the prior December 1 through May 31; a report submitted in December covers products compounded from June 1 through November 30. Each report identifies the active ingredient and strength of every compounded drug, the source of the active ingredient, and the NDC of the source drug or bulk ingredient where one exists, submitted electronically in FDA's structured product labeling format. A facility can be current on its establishment fee and still be out of compliance if a semiannual report is late or incomplete.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel before a registration renewal, a fee dispute, or a missed product report becomes an FDA compliance problem. Early legal intervention can confirm the correct fee tier, make sure a small business request is filed before its own deadline, preserve the facility's registered status, and keep the semiannual product report accurate and on time. Delaying legal review until FDA flags the facility can affect the outcome of the matter and expose the facility to risk it did not need to take.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
Health Law Alliance's compounding pharmacy defense attorneys confirm a facility's small business eligibility, prepare the annual renewal and establishment fee request, and keep semiannual product reporting current against FDA's requirements. If your outsourcing facility's registration, fee classification, or product reporting needs review before the next renewal window closes, schedule a free, confidential consultation with HLA's compounding pharmacy defense team.





